Keep Your Eyes on These Stocks: FRX, NAV, DMND, CNC, AMPE, RHHBY

Keep Your Eyes on These Stocks: FRX, NAV, DMND, CNC, AMPE, RHHBY

The following stocks have news that should keep them trading actively on Monday.

Forest Laboratories (NYSE:FRX)

The company lowered its fiscal year 2013 earnings guidance after announcing that its March patent exclusivity expiration on Lexapro, its treatment for depression, affected the company more than expected. The first prices from approved distributor Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) was lower than the company expected, cutting into royalty income.

Shares of Forest Labs are down 3.59 percent to $34.41.

Navistar International (NYSE:NAV)

Activist investor Carl Icahn increased his stake in the company, suggesting a fresh interest in the company. It has been struggling and saw two consecutive quarters of losses with its restructured management.

Shares of Navistar are up 2.61 percent to $29.10.

Diamond Foods Inc. (NYSE:DMND)

The company said it wouldn’t meet Monday’s Nasdaq deadline for filing quarterly reports. As a result, the company will likely get a delisting warning. It could appeal this to delay a potential listing pull from the exchange.

Diamond Foods will also ask for an extension for the date of its annual meeting; this isn’t likely to happen prior to July 31.

Shares of Diamond Foods are down 9.23 percent to $18.30.

Centene Corp. (NYSE:CNC) 

The company cut its full-year earnings guidance after seeing higher-than-expected medical costs in Kentucky and Texas as well as from its Celtic business. It is also prepping for a possible writedown.

Shares of Centene are down 23.06 percent to $27.29.

Ampio Pharmaceuticals Inc. (NASDAQ:AMPE)

The company announced good trial results from its retina swelling treatment due to diabetes.

Shares of Ampio Pharmaceuticals are up 6.64 percent to $3.41.

Roche Holding Ltd (RHHBY)

The company took Illumina (ILMN) off its M&A to-buy list and will now instead focus on the evolving DNA sequencing field through  internal projects and partnerships. Roche CEO Severin Schwan doesn’t plan to lose sleep over the unsuccessful bid.

LEAVE A COMMENT


Saved Articles
X
TextTExtLInkTextTExtLInk

The Life and Career of Charlie Munger

Charlie is more than just Warren Buffett’s friend and Berkshire Hathaway’s Vice Chairman – Buffett has actually credited him with redefining how he looks at investing. Now you can learn from Charlie firsthand via this incredible ebook and over a dozen other famous investor studies by signing up below:

  • Learn from the best and forever change your investing perspective
  • One incredible tidbit of knowledge after another in the page-turning masterpiece of a book
  • Discover the secrets to Charlie’s success and how to apply it to your investing
Never Miss A Story!
Subscribe to ValueWalk Newsletter. We respect your privacy.

Congrats! Are you a smart person?

We have an exclusive targeted for being a sophisticated and loyal reader.

Sign up for ValueWalkPremium today and get our exclusive content for 35% off.

Use coupon code vip19 or click on the button below

Limited time offer only ENDS 12/31/2019 or after next 25 subscribers take advantage whichever comes first – please do not share this discount with others

 

0